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Improves Sublingual MicrJournal of CardiothoracicDexmedetomidine Versus Propofol Sedation
ocirculation After Cardiac
Surgery: A Randomized Controlled TrialXu Liu, MSc,* Kai Zhang, MD,* Wei Wang, MD,* Guohao Xie, MD,* Baoli Cheng, PhD,* Yan Wang, MD,*
Yaoqin Hu, MD,† and Xiangming Fang, MD*Objectives: To compare the effects of dexmedetomidine
and propofol on sublingual microcirculation in patients after
cardiac surgery.
Design: A prospective, randomized, single-blind study.
Setting: University hospital.
Participants: Adult patients undergoing elective valve
surgery with cardiopulmonary bypass.
Interventions: On arrival in the intensive care unit (ICU),
patients were assigned randomly to receive either dexme-
detomidine (0.2-1.5 μg/kg/h) or propofol (5-50 μg/kg/min)
with open-label titration to a target Richmond Agitation-
Sedation Scale of 0 to –3.
Measurements and Main Results: Sublingual microcircula-
tion was recorded using sidestream dark-ﬁeld imaging at ICU
admission (baseline [T1]) and 4 hours (T2) and 24 hours after
ICU admission (T3). At T2, median changes in perfused small-
vessel density and the De Backer score from baseline were
signiﬁcantly greater in the dexmedetomidine group (n ¼ 29)
than in the propofol group (n ¼ 32) (1.3 v 0 mm/mm2, p ¼and Vascular Anesthesia, Vol 30, No 6 (Decemb0.025; 0.9 v –0.1/mm, p ¼ 0.005, respectively); median changes
in small-vessel density and the proportion of perfused small
vessels from baseline also tended to be higher in the dexme-
detomidine group compared with the propofol group (1.0 v –0.1
mm/mm2, p ¼ 0.050; 2.1% v 0.5%, p ¼ 0.062, respectively). At
T3, there still was a trend toward greater improvements in the
small vessel density, proportion of perfused small-vessels,
perfused small-vessel density, and De Backer score from base-
line in the dexmedetomidine group than in the propofol group.
Conclusions: This trial demonstrated that dexmedetomi-
dine sedation may be better able to improve microcirculation
in cardiac surgery patients during the early postoperative
period compared with propofol.
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
KEY WORDS: dexmedetomidine, propofol, sedation, cardiac
surgery, microcirculationFrom the Departments of *Anesthesiology and Intensive Care Unit,
First Afﬁliated Hospital, School of Medicine, Zhejiang University,
Hangzhou, Zhejiang, China; and †Anesthesiology, Children’s Hospital,
School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.MICROCIRCULATION PLAYS an important role in tissueperfusion, ﬂuid homeostasis, and the delivery of oxygen and
other nutrients.1 Impairment of sublingual microcirculation, such as
a decreased proportion and density of perfused small vessels, has
been observed in cardiac surgery patients, especially in cardiopul-
monary bypass (CPB) patients.2-5 Impaired microcirculation persists
for at least 24 hours after cardiac surgery.2 Increased micro-
circulatory ﬂow is associated with reduced organ failure in the
early stage of critical illness.6 Therefore, perioperative therapeutic
strategies to improve microcirculation may be preferred for patients
undergoing cardiac surgery with CPB.
Sedatives and analgesic medications are administered routinely
to most cardiac surgery patients to reduce pain and anxiety.7,8
Current guidelines suggest propofol and dexmedetomidine as ﬁrst-
line sedatives in the intensive care unit (ICU).9 Dexmedetomidine is
a highly selective alpha-2 agonist that has been shown to
downregulate inﬂammatory responses,10-12 restore perfused small-
vessel density (PSVD) in a rat model of surgical stress and pain,13
and increase functional capillary density in an endotoxemia rodent
model.12 However, the effects of dexmedetomidine on micro-
circulation remain unclear in patients after cardiac surgery.
Thus, the authors designed and conducted a randomized
controlled trial to test the hypothesis that dexmedetomidine
attenuated sublingual microcirculatory alterations while effec-
tively sedating mechanically ventilated patients after cardiac
valve surgery with CPB compared with propofol.This trial was registered at chictr.org.cn (ChiCTR-IPR-15006611).
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© 2016 The Authors. Published by Elsevier Inc. This is an open
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This randomized, controlled clinical trial was approved by the
Ethics Committee of the First Afﬁliated Hospital, School of
Medicine, Zhejiang University and performed in the ICU between
June and August 2015. Written informed consent was obtained
from the patient or next of kin before enrollment. The studyinclusion criteria were age 18 years or older, elective cardiac valve
surgery with CPB, and admission to the ICU intubated and
ventilated. Patients were excluded when they had at least 1 of the
following characteristics on arrival in the ICU: acute severe
neurologic disorder, mean arterial pressure less than 55 mmHg
(despite administration of appropriate intravenous volume replace-
ment and vasopressors), heart rate less than 50 beats per minute,
grade II or III atrioventricular conduction block (unless pacemaker
installed), propofol or dexmedetomidine allergy or other contra-
indications, insulin-dependent diabetes, or body mass indexZ30
kg/m2. In addition, patients who underwent reoperation, received 2
or more sedatives after randomization, and had a sedation timeo4
hours orZ24 hours also were excluded.
All patients were administered anesthesia using similar
strategies. Induction was performed with midazolam and
sufentanil, and paralysis was achieved with cisatracurium.
The anesthetic maintenance regimen was sevoﬂurane (1%-
2%) and doses of propofol and sufentanil adjusted according to
a desired target-controlled infusion. CPB was managed accord-
ing to a standard protocol. During CPB, propofol was used forer), 2016: pp 1509–1515 1509
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enrolled in the study if they were expected to require sedation
for more than 4 hours. Then, they were randomly assigned at a
1:1 ratio to receive sedation with either propofol or dexmede-
tomidine according to the random number table. The patients
and the researchers who analyzed sublingual microcirculatory
images were blinded to the group allocation.
During the study period, the mechanical ventilation param-
eters consisted of a 35% inspiratory oxygen concentration and
a positive end-expiratory pressure of 3 cmH2O. The tidal
volume was adjusted to maintain partial pressure of arterial
carbon dioxide at 35-to-45 mmHg; epinephrine and dobut-
amine were used to maintain cardiovascular stability. Sufenta-
nil was infused continuously (usually at a rate of 0.06 μg/kg/h)
for intravenous analgesia up to 48 hours postoperatively. Pain
was assessed using the Critical-Care Pain Observation Tool
(range 0 [no pain] to 8 [maximal pain]) or the Visual Analog
Scale (range 0 [no pain] to 10 [worst pain imaginable]) before
and after extubation, respectively. If the Critical-Care Pain
Observation Tool score was greater than 2,9 or if the Visual
Analog Scale score was greater than 3,14 an intravenous bolus
of extra analgesic (morphine or tramadol) was given.
Dexmedetomidine or propofol was infused continuously
without a loading dose. The sedation level was assessed using
the Richmond Agitation-Sedation Scale (RASS), which ranged
from –5 (unarousable) to 4 (combative). The assessment of the
RASS score was performed every 2 hours or more often if
required (eg, patient’s condition changed). The sedative was
titrated to maintain the RASS score between 0 and –3.15 The
maximum intravenous infusion speed of dexmedetomidine was
not greater than 1.5 μg/kg/h, whereas that of propofol was not
greater than 50 μg/kg/min.9 The infusion of sedative was
stopped before extubation at the discretion of the attending
physicians.
Microvascular blood ﬂow was visualized using sidestream
dark-ﬁeld (SDF) imaging with a 5-fold magniﬁcation lens.16
SDF images were recorded as soon as possible after ICU
admission and before the infusion of sedatives (baseline [T1])
and 4 (T2) and 24 hours after ICU admission (T3). The optical
probe was applied to the sublingual mucosa after gently
removing saliva with cotton swabs. Images of approximately
15-second duration were acquired from at least 5 different
ﬁelds at each time point. SDF images were analyzed off-line
using dedicated software (Automated Vascular Analysis 3.2;
Academic Medical Center, Amsterdam, The Netherlands) by 2
investigators unaware of the origin of the video clips.
Only parameters for the small vessels (less than 20-μm
diameter) were calculated.17,18 The De Backer score was
calculated as the number of small vessels crossing the lines
(3 equidistant horizontal and 3 equidistant vertical lines drawn
on the screen) divided by the total length of the lines.16,17
Small-vessel density (SVD) was calculated using the software
as the total small vessel length divided by the total area of the
image.16,17 The proportion of perfused small vessels (PPV) was
calculated as 100 multiplied by the number of small vessels
with continuous ﬂow (normal and sluggish) divided by the total
number of small vessels.16,17 PSVD was calculated by multi-
plying the SVD by the PPV.16,17 For each patient, the values
obtained from 5 sites were averaged.17 Improvement inmicrocirculation was represented by changes in the PSVD
greater than 10% from baseline.2
Clinical parameters, such as temperature, heart rate, and
arterial pressure, also were obtained at T1, T2, and T3. Arterial
blood samples were withdrawn simultaneously, and blood
gases, hemoglobin, and lactate concentrations were measured
(GEM Premier 3000; Instrumentation Laboratory, Bedford,
MA). The Acute Physiology and Chronic Health Evaluation
II score19 and the Sequential Organ Failure Assessment score20
were obtained on ICU admission.
Clinical adverse events were recorded during the ICU stay,
which were deﬁned as follows: hypotension (a systolic blood
pressure less than 90 mmHg or mean arterial pressure less than
65 mmHg), bradycardia (heart rate less than 60 beats/min),
postoperative nausea and vomiting, and atrial ﬁbrillation and
delirium (confusion assessment method for the ICU). Intuba-
tion time (from ICU admission to the time of extubation) also
was recorded.
Given that PSVD is a major parameter that reﬂects micro-
circulation,2,3,5,12,13 PSVD at T2 was the primary endpoint in
this study. Based on the preliminary study, for a power of 0.8
and a 2-sided α level of 0.05, a sample of 28 patients in each
group was considered to be appropriate to detect a 10%
difference of PSVD between the 2 groups at T2. Considering
a compliance rate of 80%, 68 patients were enrolled in the
study. Patient data were described using descriptive statistics
and presented as medians (interquartile range), unless indicated
otherwise. All continuous variables were assessed for normality
using the Shapiro-Wilk test. Differences between groups were
tested using parametric student’s t test or the Mann-Whitney U
test for nonparametric data. Microcirculatory and hemody-
namic data over time were analyzed using repeated-measures
analysis of variance. Categorical variables were compared
using the Fisher exact test. SPSS, Version 16.0 for Windows
(SPSS, Chicago, IL), was used for statistical analysis. A p
value less than 0.05 (2-sided) was considered statistically
signiﬁcant.RESULTS
A total of 174 patients who underwent cardiac surgery were
assessed for eligibility (Fig 1). After 106 patients were
excluded, including 38 patients who refused to participate, 68
patients were assigned randomly to the following: 34 patients
received propofol and 34 patients received dexmedetomidine.
In the propofol group, 2 patients were infused with sedative for
more than 24 hours. In the dexmedetomidine group, 3 patients
were switched to propofol due to the request of the attending
physicians, 1 patient withdrew consent, and 1 patient was
infused with sedative for more than 24 hours. Ultimately, 32
patients were analyzed in the propofol group and 29 patients
were analyzed in the dexmedetomidine group. There were no
signiﬁcant differences in demographic data and baseline
characteristics between the groups (Table 1).
The SVD, PPV, PSVD, and De Backer score improved over
time in both groups (Table 2). However, PSVD and the De
Backer score changed differently over time in the 2 groups in
favor of the dexmedetomidine group (for time  group; p ¼
0.048, p ¼ 0.014, respectively; Table 2). Furthermore, at T2,
Fig 1. Flow diagram of participant selection.
DEXMEDETOMIDINE IMPROVES SUBLINGUAL MICROCIRCULATION 1511changes in the PSVD and De Backer score from baseline were
signiﬁcantly greater in the dexmedetomidine group than in the
propofol group (1.3 [–0.2 to 2.8] v 0 [–1.1 to 0.9] mm/mm2,
p ¼ 0.025; 0.9 [0.2 to 2.3] v –0.1 [–1.3 to 1.1] /mm,
p ¼ 0.005, respectively; Fig 2); changes in SVD and PPV
from baseline also tended to be higher in the dexmedetomidineTable 1. Baseline Data for All Patients at Enrollment
Characteristics
Propofol
(n ¼ 32)
Dexmedetomidine
(n ¼ 29) p Value
Age, y 55 (48-62) 53 (48-63) 0.737
Female, n (%) 17 (53) 19 (66) 0.435
BMI, kg/m2 21.2 (19.6-25.3) 23.2 (20.9-24.1) 0.237
Hypertension, n (%) 8 (25) 8 (28) 40.999
Diabetes, n (%) 2 (6) 3 (10) 0.662
Smoking history, n (%) 10 (31) 6 (21) 0.395
Preoperative LVEF, % 62 (57-69) 62 (56-70) 0.556
NYHA class 2 (2-3) 3 (2-3) 0.380
Type of surgery, n (%) 0.348
Valve repair 3 (9) 3 (10)
MVR 6 (19) 6 (21)
AVR 4 (13) 6 (21)
MVRþAVR 9 (28) 3 (10)
MVRþTV Repair 5 (16) 9 (31)
MVRþAVRþTV
Repair
5 (16) 2 (7)
CPB time, min 68 (54-80) 73 (60-88) 0.194
Cross-clamp time, min 46 (34-59) 51 (35-64) 0.649
APACHE II score 15 (12-18) 16 (14-18) 0.275
SOFA score 5 (5-6) 5 (5-6) 0.905
NOTE. Data presented as median (interquartile range) unless
otherwise stated.
Abbreviations: APACHE, Acute Physiology and Chronic Health
Evaluation; AVR, aortic valve replacement; BMI, body mass index;
CPB, cardiopulmonary bypass; LVEF, left ventricular ejection fraction;
MVR, mitral valve replacement; NYHA, New York Heart Association;
SOFA, Sequential Organ Failure Assessment; TV, tricuspid valve.group compared with the propofol group (1.0 [–0.6 to 2.6]
v –0.1 [–1.2 to 0.9] mm/mm2, p ¼ 0.050; 2.1% [0.2% to 4.1%]
v 0.5% [–1.2% to 3.3%], p ¼ 0.062, respectively; Fig 2). In
addition, at T2, an improvement in microcirculation was
present in 13 (44.8%) and 5 (15.6%) patients in the dexmede-
tomidine and propofol groups, respectively (p ¼ 0.023).
At T3, an improvement in microcirculation was present in
18 (62.1%) and 19 (59.4%) patients in the dexmedetomidine
and propofol groups, respectively. However, at T3, there still
was a trend toward greater improvements in the SVD, PPV,
PSVD and De Backer score from baseline in the dexmedeto-
midine group than in the propofol group (2.8 [–0.4 to 4.6] v 2.3
[0.1 to 3.1] mm/mm2, p ¼ 0.213; 2.5% [1.6% to 4.7%] v 2.2%
[0% to 3.9%], p ¼ 0.289; 2.8 [0.1 to 5.3] v 2.3 [0.3 to 3.3]
mm/mm2, p ¼ 0.187; 2.0 [0 to 3.2] v 1.5 [0 to 2.4] /mm,
p ¼ 0.193, respectively; Fig 2).
There were no signiﬁcant differences between the 2 groups
regarding clinical parameters, including the temperature, mean
arterial pressure, heart rate, and hemoglobin and arterial blood
lactate levels at each time point (see Table 2). Changes in the
temperature, mean arterial pressure, heart rate, and hemoglobin
and arterial blood lactate levels over time were similar in both
groups (Table 2). Moreover, no signiﬁcant difference was
found in the use of epinephrine and dobutamine between the 2
groups at each time point (Table S1).
The scores for sedation and analgesia were similar in the 2
groups at each time point (Table S2). The median (interquartile
range) dexmedetomidine infusion rate was 0.67 (0.38-0.76) μg/
kg/h, and the median (interquartile range) propofol infusion
rate was 0.90 (0.73-1.19) mg/kg/h throughout their duration
(864 [681-1,072] v 851 [708-984] min; p ¼ 0.355). For 24
hours postoperatively, more patients were given morphine or
tramadol in the dexmedetomidine group than in the propofol
group (1 [3.1%] v 7 [24.1%]; p ¼ 0.022 ). In addition, the
intubation time was similar between the dexmedetomidine
group and propofol group (18.9 [17.7-22.0] v 21.0 [17.5-
Table 2. Microcirculatory Variables and Clinical Parameters at Each Time Point
T1 T2 T3
SVD, mm/mm2
Propofol* 14.1 (12.4-16.4) 13.8 (11.4-16.9) 15.6 (13.5-17.9)
Dexmedetomidine* 13.9 (11.1-15.7) 15.4 (12.1-17.7) 16.1 (14.3-18.9)
PSVD, mm/mm2†
Propofol* 13.4 (11.2-15.4) 13.4 (10.8-15.9) 15.2 (13.2-16.8)
Dexmedetomidine* 12.8 (10.4-15.0) 14.9 (11.5-17.1) 15.3 (13.8-17.9)
PPV, %
Propofol* 95.5 (92.8-96.9) 95.4 (94.0-97.2) 96.8 (95.5-98.2)
Dexmedetomidine* 93.6 (92.3-95.4) 96.2 (94.2-97.3) 96.2 (95.1-97.9)
De Backer score, n/mm†
Propofol* 8.9 (8.1-10.2) 8.6 (6.9-10.5) 9.8 (8.8-11.8)
Dexmedetomidine* 8.7 (7.0-9.9) 9.6 (8.1-11.5) 10.5 (9.0-11.7)
Temperature, 1C
Propofol* 36.4 (36.0-36.8) 37.5 (37.1-38.0) 37.8 (37.2-38.2)
Dexmedetomidine* 36.2 (35.7-36.4) 37.3 (36.8-37.5) 37.8 (37.3-38.0)
MAP, mmHg
Propofol 79 (72-85) 78 (72-82) 78 (72-83)
Dexmedetomidine 76 (74-85) 79 (76-88) 81 (74-88)
Heart rate, bpm
Propofol 94 (75-110) 95 (84-103) 95 (85-112)
Dexmedetomidine 92 (81-110) 87 (79-100) 100 (90-110)
Hemoglobin, g/dL
Propofol 9.0 (8.2-10.4) 9.2 (8.4-10.7) 8.0 (7.5-9.2)
Dexmedetomidine 9.6 (8.4-10.7) 9.0 (8.1-10.4) 8.4 (7.5-9.8)
Serum lactate, mmol/L
Propofol 5.1 (3.5-6.3) 3.8 (2.8-5.5) 2.1 (1.5-3.0)
Dexmedetomidine 5.5 (3.7-6.4) 4.2 (3.0-6.4) 2.3 (1.3-3.0)
NOTE. Data presented as median (interquartile range).
Abbreviations: ICU, intensive care unit; MAP, mean arterial pressure; PPV, proportion of perfused small-vessels; PSVD, perfused small-vessel
density; SVD, small-vessel density; T1, ICU admission; T2, 4 hours after ICU admission; T3, 24 hours after ICU admission.
*p o 0.05 values over time (repeated measures analysis of variance).
†p o 0.05 between groups over time (repeated measures analysis of variance).
LIU ET AL151222.5] h; p ¼ 0.784). The incidences of adverse events were
comparable in the 2 groups (Table 3).
DISCUSSION
This was the ﬁrst study to compare the effects of the ﬁrst-
line sedatives dexmedetomidine and propofol on changes of
microcirculation in patients after cardiac surgery. This study
showed that dexmedetomidine sedation contributed to an
earlier and greater improvement in sublingual microcirculation
in patients after valve surgery with CPB compared with
propofol. Recent studies have shown that the use of dexmede-
tomidine during the perioperative period decreased the inci-
dence of postoperative complications, including delirium, in
patients undergoing cardiac surgery,21-23 which was supported
by the ﬁndings in the study presented here.
As a selective and potent alpha2-receptor agonist, dexme-
detomidine has the following dual vasomotor effects: the
activation of alpha-2-adrenoceptors on vascular smooth muscle
cells results in vasoconstriction, whereas the activation of
alpha-2-adrenoceptors on endothelial cells and inhibition of
sympathetic nervous activity cause vasodilation.12,13,24,25 The
net effect of alpha-2-adrenergic stimulation is usually vaso-
dilation.13,25,26 However, propofol administration also induces
generalized vasodilation throughout the arteriolar tree.27 In the
study presented here, hypotension occurred with similar
prevalence in the 2 groups, and there were no differences inthe macrodynamics and use of epinephrine and dobutamine
between the 2 groups. Furthermore, Miranda et al found that
dexmedetomidine did not alter the mean internal arteriolar and
venular diameters in the lipopolysaccharide model.12 There-
fore, the authors of this study speculated that an earlier and
greater improvement in microvascular perfusion induced by
dexmedetomidine might not be due to a direct vasoactive
effect.
Recent studies have demonstrated that dexmedetomidine
could attenuate inﬂammatory responses, decrease leukocyte-
endothelial interactions, and produce mild hypocoagulation,
which could assist in the recruitment of microcirculation.11-13
In a surgical stress and pain rat model, PSVD of the intestinal
mucosa and muscle were signiﬁcantly higher in a
dexmedetomidine-treated group than in the control group.13
The beneﬁt of dexmedetomidine on microcirculation was
conﬁrmed in an endotoxemia rodent model, and the inves-
tigators reported that dexmedetomidine decreased leukocyte-
endothelial interactions and was associated with the signiﬁcant
attenuation of capillary perfusion deﬁcits.12 These results were
in accordance with those of the study presented here, which
demonstrated an increase of small vessels with continuous ﬂow
during dexmedetomidine infusion. In addition, studies have
shown that propofol infusion for anesthesia reduced capillary
blood ﬂow in young patients who underwent transvaginal
oocyte retrieval,27 and changing the sedative infusion from
Fig 2. Changes in microcirculatory perfusion parameters from
baseline to T2 and T3. The microcirculatory perfusion parameters
included (A) SVD; (B) PSVD; (C) PPV; and (D) De Backer score.
Propofol, sedation with propofol (n ¼ 32); dexmedetomidine, seda-
tion with dexmedetomidine (n ¼ 29). *po 0.05 compared with the
propofol group. Bar charts demonstrate the mean; error bars indicate
the standard error of the mean (above the mean). PPV, proportion of
perfused small vessels; PSVD, perfused small-vessel density; SVD,
small-vessel density; T2, 4 hours after ICU admission; T3, 24 hours
after ICU admission.
Table 3. Adverse Events During ICU Stay
Propofol (n ¼ 32) Dexmedetomidine (n ¼ 29) p Value
Hypotension 11 (34) 9 (31) 0.793
Bradycardia 1 (3) 5 (17) 0.093
Nausea/vomiting 7 (22) 3 (10) 0.307
Delirium 2 (6) 0 (0) 0.493
Atrial ﬁbrillation 19 (59) 17 (59) 40.999
New-onset AF 5/18 (28) 1/11 (9) 0.362
NOTE. Data presented as n (%).
Abbreviations: AF, atrial ﬁbrillation; ICU, intensive care unit.
DEXMEDETOMIDINE IMPROVES SUBLINGUAL MICROCIRCULATION 1513propofol to midazolam resulted in an improvement of the
sublingual microcirculation in patients with septic shock.28
Although propofol, which acts by potentiating gamma amino-
butyric acid type-A receptors,29 also attenuates inﬂammatory
responses,30,31 a clinical study showed that the levels of tumor
necrosis factor-alpha, interleukin-1, and interleukin-6 were
signiﬁcantly higher in the propofol group than in the dexme-
detomidine group during sedation for patients after abdominal
surgery.32 Proinﬂammatory cytokines induced endothelial-
leukocyte cell interactions,33 resulting in the obstruction of
small vessels by leukocyte plugs21 and the activation of the
coagulation system, which may lead to microvascular throm-
bosis.34 Cardiac surgery with CPB induced a systemic inﬂam-
matory response.8 Dexmedetomidine lacked clinically
signiﬁcant anticholinergic effects and attenuated the inﬂamma-
tory response of CPB.11,23 In the study presented here, C-
reactive protein and the neutrophil-lymphocyte ratio (NLR)
tended to be lower in the dexmedetomidine group than that in
the propofol group on the morning of the ﬁrst postoperative
day (Table S3). In addition, the change in NLR from ICU
admission to the morning of the ﬁrst postoperative day was
signiﬁcantly lower in the dexmedetomidine group than in the
propofol group (Fig S1). The NLR is an emerging biomarker of
inﬂammation, and elevated NLR predicts a poorer outcome in
cardiovascular surgery.35,36 Therefore, dexmedetomidine showed
stronger inhibitory effects on the inﬂammatory response than
propofol, which may have been one possible reason why changes
in the PSVD and De Backer score were signiﬁcantly greater in the
dexmedetomidine group than in the propofol group at T2.
This study had several limitations. First, only valve surgery
patients were included; thus, further studies are required to
conﬁrm whether dexmedetomidine also induces earlier
improvements of microcirculation than propofol for sedation
in patients after other types of major surgery. Second, the
effects of the sedatives should be interpreted with the target of
light-to-moderate sedation and the concomitant use of sufenta-
nil and dobutamine. There may be interactions between the
concomitant use of drugs and dexmedetomidine/propofol, and
the results might have been different if different analgesics and
pressors had been chosen. Third, a spontaneous improvement
of the microcirculatory parameters over time after surgery in
both groups may have interfered with the microcirculatory
effects of dexmedetomidine and propofol. However, it may not
be appropriate that the intubated and ventilated patients were
not given sedatives in the early postoperative period. Finally,
the sublingual area may not be representative of other vascular
LIU ET AL1514beds, although some studies have shown that sublingual micro-
circulation could reﬂect intestinal microcirculation.37,38 How-
ever, the sublingual mucosa currently is the most commonly
used site for SDF measurements in humans.39
In summary, this was the ﬁrst prospective, randomized clinical
study to investigate the effects of dexmedetomidine and propofol
on sublingual microcirculation in patients who underwent valve
surgery. These results demonstrated that dexmedetomidine may
accelerate the recovery of sublingual microcirculatory perfusion in
patients after valve surgery compared with propofol. Larger
randomized controlled trials should be performed to conﬁrm the
improvements in microcirculation induced by dexmedetomidine.ACKNOWLEDGMENTS
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